Morgan Stanley analyst Steve Beuchaw believes Danaher (DHR) is creating value with its Dental spin off, contending that the move will likely create a "RemainCo" with a faster growing top-line and higher margins, which should support multiple expansion. Investor feedback so far applies a Dentsply Sirona (XRAY) EBITDA multiple on Dental and a Tools industry multiple on the RemainCo, but Beuchaw believes this too conservative. Using his own free cash flow valuation, he could see the RemainCo plus Dental SpinCo being worth $120-$125 per share. Beuchaw raised his price target on Danaher to $122 from $120 and keeps an Overweight rating on the shares.

Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.

Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.

Notable gainers among liquid option names this morning include Globe Life (GL) $71.33 +4.94, Super Micro (SMCI) $764.85 +47.83, Danaher (DHR) $250.88 +14.79, Kimberly Clark (KMB) $136.87 +7.94, and General Motors (GM) $45.38 +2.17.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here